Kelsey Flint
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelsey Flint has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Larry A. Allen
Division of Cardiology, Department of Medicine, University of Colorado, Aurora (L.A.A.).
3 shared publications - Christopher E. Knoepke
University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States of America
2 shared publications - Daniel D. Matlock
Adult and Child Center for Outcomes Research and Delivery Science, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
2 shared publications - David B. Bekelman
Department of Medicine, Department of Veterans Affairs (D.B.B.), Eastern Colorado Health Care System, Aurora, Colorado, USA; Division of General Internal Medicine (D.B.B.), University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
2 shared publications David Bekelman
Colorado Cardiovascular Outcomes Research Consortium, Denver, Colorado, USA; VA Eastern Colorado Health Care System, Denver, Colorado, USA; Department of Medicine, Division of General Internal Medicine, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, Colorado, USA
2 shared publicationsEllen Brinza
University of Colorado, Anschutz Medical Campus Aurora Colorado USA
2 shared publications
Latest Publications
- 13 May 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (6) , 1931-1932
Reply to: Comment on: Malnutrition in heart failure with preserved ejection fraction
This letter comments on the letter by May in this issue.
- 13 May 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (6) , 1931-1932
Reply to: Comment on: Malnutrition in heart failure with preserved ejection fraction
This letter comments on the letter by May in this issue.
- 14 September 2023
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 71 (11) , 3354-3356
Malnutrition in heart failure with preserved ejection fraction: More than meets the eye
This editorial comments on the article by Zainul et al . in this issue.
- 14 September 2023
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 71 (11) , 3354-3356
Malnutrition in heart failure with preserved ejection fraction: More than meets the eye
This editorial comments on the article by Zainul et al . in this issue.
- Open Access
Cardiac Rehabilitation Participation in Heart Failure Over Time: An Analysis of the Colorado All Payer Claims Database
Background Despite CMS coverage expansion supporting cardiac rehabilitation (CR) in patients with heart failure (HF) in 2014, data suggest that utilization among patients with HF is low. We describe CR participation and adherence among HF patients in Colorado. Methods Data from the Colorado All-Payer Claims Database from 2010-2018 were used. Patients with HF were identified by ≥2 claims with a HF diagnosis code, then grouped by type of HF (HFrEF, HFpEF, unspecified). CR participation and adherence were identified using CR CPT codes. Participation rates were calculated by quarter of each year. Cochran-Armitage tests determined whether temporal trends were significant. Association between CR participation and payer source was examined in adjusted logistic regression models. Results 263,476 patients with HF were identified. 4.77% of all HF patients attended CR at least once; this result was similar for HFpEF (4.35%), unspecified HF (4.15%), and higher in the HFrEF group (8.25%). Overall adherence was poor (median 8 visits, IQR 3-18; full adherence=36 visits). CR participation over time increased (PConclusions In the state of Colorado, CR participation improved from 2010-2018 among all patients with HF. Our data suggest that payer source, race, sex and presence of another indication for CR drive CR participation in patients with HF.
Open AccessCardiac Rehabilitation Participation in Heart Failure Over Time: An Analysis of the Colorado All Payer Claims Database
Background Despite CMS coverage expansion supporting cardiac rehabilitation (CR) in patients with heart failure (HF) in 2014, data suggest that utilization among patients with HF is low. We describe CR participation and adherence among HF patients in Colorado. Methods Data from the Colorado All-Payer Claims Database from 2010-2018 were used. Patients with HF were identified by ≥2 claims with a HF diagnosis code, then grouped by type of HF (HFrEF, HFpEF, unspecified). CR participation and adherence were identified using CR CPT codes. Participation rates were calculated by quarter of each year. Cochran-Armitage tests determined whether temporal trends were significant. Association between CR participation and payer source was examined in adjusted logistic regression models. Results 263,476 patients with HF were identified. 4.77% of all HF patients attended CR at least once; this result was similar for HFpEF (4.35%), unspecified HF (4.15%), and higher in the HFrEF group (8.25%). Overall adherence was poor (median 8 visits, IQR 3-18; full adherence=36 visits). CR participation over time increased (PConclusions In the state of Colorado, CR participation improved from 2010-2018 among all patients with HF. Our data suggest that payer source, race, sex and presence of another indication for CR drive CR participation in patients with HF.
- 1 March 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (3) , e008679
“My Amazing Heart”: A Patient’s Simple Request to Change Outdated Heart Failure Labels
- 1 March 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (3) , e008679
“My Amazing Heart”: A Patient’s Simple Request to Change Outdated Heart Failure Labels
- 1 September 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (9) , e008860
Untangling the Sex-Frailty Paradox in Heart Failure
- 1 September 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (9) , e008860
Untangling the Sex-Frailty Paradox in Heart Failure
- 1 April 2021
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (4) , 497-500
Social Determinants of Health and Rates of Implantation for Patients Considering Destination Therapy Left Ventricular Assist Device
- 1 April 2021
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 27 (4) , 497-500
Social Determinants of Health and Rates of Implantation for Patients Considering Destination Therapy Left Ventricular Assist Device
- Open Access
- 4 September 2020
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 4 (1) , e18101
“I Like the Idea of It…But Probably Wouldn’t Use It” - Health Care Provider Perspectives on Heart Failure mHealth: Qualitative Study
Background: Many mobile health (mHealth) technologies exist for patients with heart failure (HF). However, HF mhealth lacks evidence of efficacy, caregiver involvement, and clinically useful real-time data. Objective: We aim to capture health care providers’ perceived value of HF mHealth, particularly for pairing patient–caregiver-generated data with clinical intervention to inform the design of future HF mHealth. Methods: This study is a subanalysis of a larger qualitative study based on interviewing patients with HF, their caregivers, and health care providers. This analysis included interviews with health care providers (N=20), focusing on their perceived usefulness of HF mHealth tools and interventions. Results: A total of 5 themes emerged: (1) bio-psychosocial-spiritual monitoring, (2) use of sensors, (3) interoperability, (4) data sharing, and (5) usefulness of patient-reported outcomes in practice. Providers remain interested in mHealth technologies for HF patients and their caregivers. However, providers report being unconvinced of the clinical usefulness of robust real-time patient-reported outcomes. Conclusions: The use of assessments, sensors, and real-time data collection could provide value in patient care. Future research must continually explore how to maximize the utility of mHealth for HF patients, their caregivers, and health care providers.
- 4 September 2020
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 4 (1) , e18101
Open Access“I Like the Idea of It…But Probably Wouldn’t Use It” - Health Care Provider Perspectives on Heart Failure mHealth: Qualitative Study
Background: Many mobile health (mHealth) technologies exist for patients with heart failure (HF). However, HF mhealth lacks evidence of efficacy, caregiver involvement, and clinically useful real-time data. Objective: We aim to capture health care providers’ perceived value of HF mHealth, particularly for pairing patient–caregiver-generated data with clinical intervention to inform the design of future HF mHealth. Methods: This study is a subanalysis of a larger qualitative study based on interviewing patients with HF, their caregivers, and health care providers. This analysis included interviews with health care providers (N=20), focusing on their perceived usefulness of HF mHealth tools and interventions. Results: A total of 5 themes emerged: (1) bio-psychosocial-spiritual monitoring, (2) use of sensors, (3) interoperability, (4) data sharing, and (5) usefulness of patient-reported outcomes in practice. Providers remain interested in mHealth technologies for HF patients and their caregivers. However, providers report being unconvinced of the clinical usefulness of robust real-time patient-reported outcomes. Conclusions: The use of assessments, sensors, and real-time data collection could provide value in patient care. Future research must continually explore how to maximize the utility of mHealth for HF patients, their caregivers, and health care providers.
- Open Access
- 11 March 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (3) , 811-824
Variation in Clinical and Patient-Reported Outcomes Among Complex Heart Failure with Preserved Ejection Fraction Phenotypes
Aims The aim of this study is to use six previously described heart failure with preserved ejection fraction (HFpEF) phenotypes to describe differences in (i) the biological response to spironolactone, (ii) clinical endpoints, and (iii) patient‐reported health status by HFpEF phenotype and treatment arm in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). Methods and results We analysed 1767 patients in TOPCAT from the Americas. Using 11 clinical variables, patients were classified according to six HFpEF phenotypes previously identified in the I‐PRESERVE and CHARM‐Preserved studies. Kansas City Cardiomyopathy Questionnaire (KCCQ) measured health status. All phenotypes showed increase in potassium with spironolactone, although only three phenotypes showed significant increase in creatinine, and two phenotypes showed significant decrease in systolic blood pressure. Rate of the TOPCAT primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) differed by HFpEF phenotype (P < 0.001) but not by treatment arm within each HFpEF phenotype. Baseline KCCQ score differed by HFpEF phenotype (P < 0.001), although some phenotypes with poor health status had lower rates of the TOPCAT primary outcome, and some phenotypes with better health status had higher rates of the TOPCAT primary outcome. However, within 3/6 phenotypes, higher baseline KCCQ score was associated with lower risk of the TOPCAT primary outcome. Change in KCCQ scores at 4 and 12 months did not differ among HFpEF phenotypes overall or by treatment arm. Conclusions Complex, data‐driven HFpEF phenotypes differ according to biological response to spironolactone, baseline health status, and clinical endpoints. These differences may inform the design of targeted clinical trials focusing on improvement in outcomes most relevant for specific HFpEF phenotypes.
- 11 March 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (3) , 811-824
Open AccessVariation in Clinical and Patient-Reported Outcomes Among Complex Heart Failure with Preserved Ejection Fraction Phenotypes
Aims The aim of this study is to use six previously described heart failure with preserved ejection fraction (HFpEF) phenotypes to describe differences in (i) the biological response to spironolactone, (ii) clinical endpoints, and (iii) patient‐reported health status by HFpEF phenotype and treatment arm in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). Methods and results We analysed 1767 patients in TOPCAT from the Americas. Using 11 clinical variables, patients were classified according to six HFpEF phenotypes previously identified in the I‐PRESERVE and CHARM‐Preserved studies. Kansas City Cardiomyopathy Questionnaire (KCCQ) measured health status. All phenotypes showed increase in potassium with spironolactone, although only three phenotypes showed significant increase in creatinine, and two phenotypes showed significant decrease in systolic blood pressure. Rate of the TOPCAT primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) differed by HFpEF phenotype (P < 0.001) but not by treatment arm within each HFpEF phenotype. Baseline KCCQ score differed by HFpEF phenotype (P < 0.001), although some phenotypes with poor health status had lower rates of the TOPCAT primary outcome, and some phenotypes with better health status had higher rates of the TOPCAT primary outcome. However, within 3/6 phenotypes, higher baseline KCCQ score was associated with lower risk of the TOPCAT primary outcome. Change in KCCQ scores at 4 and 12 months did not differ among HFpEF phenotypes overall or by treatment arm. Conclusions Complex, data‐driven HFpEF phenotypes differ according to biological response to spironolactone, baseline health status, and clinical endpoints. These differences may inform the design of targeted clinical trials focusing on improvement in outcomes most relevant for specific HFpEF phenotypes.
- 1 March 2020
- Published by Wolters Kluwer Health in Journal of Cardiopulmonary Rehabilitation and Prevention
- Vol. 40 (2) , 72-78
Cardiac Rehabilitation in Frail Older Adults With Cardiovascular Disease
Older adults with cardiovascular disease (CVD) pose challenges to cardiac rehabilitation (CR) clinicians because their disease is often coupled to physical frailty. Older patients with CVD and frailty may be less likely to tolerate conventional CR exercise training due to multidimensional (ie, strength, mobility, and balance) physical impairments. Furthermore, conventional CR typically emphasizes endurance training without addressing the intrinsic skeletal muscle impairments of frail patients that often manifest as deficits in strength, mobility, and balance, undercutting feasibility and any likely benefits. However, if appropriately modified to meet the needs of frail older adults, CR may be a powerful tool for this challenging population. To best serve frail, older adults with CVD, CR programs can incorporate well-validated strategies to assess frailty and physical function that also fit within the workflows and patient populations of individual programs. Such frailty assessments provide opportunities to identify specific targets (eg, weakness) that need to be addressed before a subsequent aerobic training program can be successfully implemented and sustained. The current review focuses on the use of physical frailty measures in older adults with CVD, with practical considerations for their clinical use in contemporary CR, as well as directions for future research.
- 1 March 2020
- Published by Wolters Kluwer Health in Journal of Cardiopulmonary Rehabilitation and Prevention
- Vol. 40 (2) , 72-78
Cardiac Rehabilitation in Frail Older Adults With Cardiovascular Disease
Older adults with cardiovascular disease (CVD) pose challenges to cardiac rehabilitation (CR) clinicians because their disease is often coupled to physical frailty. Older patients with CVD and frailty may be less likely to tolerate conventional CR exercise training due to multidimensional (ie, strength, mobility, and balance) physical impairments. Furthermore, conventional CR typically emphasizes endurance training without addressing the intrinsic skeletal muscle impairments of frail patients that often manifest as deficits in strength, mobility, and balance, undercutting feasibility and any likely benefits. However, if appropriately modified to meet the needs of frail older adults, CR may be a powerful tool for this challenging population. To best serve frail, older adults with CVD, CR programs can incorporate well-validated strategies to assess frailty and physical function that also fit within the workflows and patient populations of individual programs. Such frailty assessments provide opportunities to identify specific targets (eg, weakness) that need to be addressed before a subsequent aerobic training program can be successfully implemented and sustained. The current review focuses on the use of physical frailty measures in older adults with CVD, with practical considerations for their clinical use in contemporary CR, as well as directions for future research.